There is increasing interest in using pharmacogenetics to ‘individualise medicine’, however, the results of this study indicate that in a cancer population genotyping for CYP2C19 would significantly underestimate the number of phenotypic PM of drugs, such as cyclophosphamide, which may be metabolised by this enzyme. The gene discussed is CYP2C19; the disease is cancer.